Goldman Sachs keeps a Buy rating with a A$309 price target on CSL, which is being added to the firm’s new “APAC Conviction List – Directors’ Cut.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CSLLY:
- CSL’s and Arcturus Therapeutics’ mRNA vaccine for COVID approved in Japan
- CSL upgraded to Buy from Neutral at Goldman Sachs
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue